Ionis Pharma holder to sell 6,999 shares

Ionis Pharmaceuticals has a notice of proposed sale under Rule 144 for 6,999 shares of its common stock.

Accepted by SEC EDGAR 01/16/2026 - 06:55 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals has a notice of proposed sale under Rule 144 for 6,999 shares of its common stock. The shares are expected to be sold on or about 01/16/2026 through broker Morgan Stanley Smith Barney on the NASDAQ market, with an aggregate market value of $559,920. The filing notes that these shares were acquired on 01/15/2026 as restricted stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation. The filing also reports that 161,974,393 shares of Ionis common stock were outstanding, providing context for the planned sale size.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Ionis Pharmaceuticals (IONS) disclose?

The Form 144 discloses a planned sale of 6,999 shares of Ionis Pharmaceuticals common stock, to be executed through Morgan Stanley Smith Barney on the NASDAQ.

How many Ionis Pharmaceuticals (IONS) shares are planned to be sold and at what value?

The notice covers 6,999 common shares of Ionis Pharmaceuticals with an aggregate market value of $559,920 as reported in the filing.

When were the Ionis Pharmaceuticals (IONS) shares acquired and how?

The 6,999 shares were acquired on 01/15/2026 as RSUs granted under the 2011 Equity Incentive Plan, delivered as compensation.

On which exchange will the Ionis Pharmaceuticals (IONS) shares be sold and through which broker?

The Form 144 indicates the shares are to be sold on NASDAQ through broker Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036.

How many Ionis Pharmaceuticals (IONS) shares were outstanding according to this Form 144?

The filing states that there were 161,974,393 shares of Ionis Pharmaceuticals common stock outstanding, providing context for the proposed 6,999-share sale.

What is the nature of consideration for the Ionis Pharmaceuticals (IONS) shares being sold?

The filing states that the 6,999 shares were received as compensation, specifically RSUs granted under the 2011 Equity Incentive Plan and settled on 01/15/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813775
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Baroldi Joseph
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	6999	559920.00	161974393	01/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/15/2026	RSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			6999	01/15/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	01/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph T. Baroldi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)